push back forecast launch date alzheim drug aducanumab
six month line new guidanc firm develop partner
result cut revenu estim op estim
trim target seem like
eisai share sell back news confid ultim
approv unchang reiter buy rate
impact oper earn call mention
sever member team charg make applic approv
aducanumab directli affect also appear
complex submiss requir detail time-consum
interact fda compani may origin anticip
analyst seem surpris learn pre-bla meet
fda applic approv final hand compani
say alreadi begun submit certain modul pre-clin data
modul make roll submiss might help speed process
process begun europ japan compani say begun
discuss applic approv regul europ japan
still confid reiter confid aducanumab dataset
compani said new question dataset arisen
reiter confid success applic ultim approv
multi-billion dollar opportun consid alzheim
patient us almost japan effect treatment could potenti
achiev peak sale excess compani succeed develop
early-stag patient conveni subcutan formul
opportun could sever time larger still
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
return average equiti
aducanumab approv fda
go achiev peak sale excess
also estim anti-canc drug lenvima achiev
sale arriv price
target appli histor averag ev/cor ebitda
multipl base-cas estim firm
possibl aducanumab could achiev peak
sale excess also possibl
sale estim lenvima
sale sale could higher merck
eisai succeed develop lenvima use
combin drug keytruda
also possibl alzheim
test phase trial might also succeed
clinic develop might add billion
dollar firm revenu like boost firm
earn multipl well upsid scenario price
target base scenario wherebi
market becom bullish prospect
aducanumab ev/cor ebitda multipl
expand
biggest downsid risk aducanumab fail
get approv fda also risk lenvima
fail grow quickli expect may
due levnima clinic data compel
expect compet product take share
away lenvima downsid scenario price target
line target eisai
includ aducanumab forecast
revenu
estim cursori examin consensu
indic major sell-sid
analyst done
eisai partner plan submit
aducanumab fda approv earli
possibl drug approv
pleas see import disclosur inform page report
pleas see import disclosur inform page report
pleas see import disclosur inform page report
ex-r oper oper oper ebitda non-control profit current current fix non-curr current lt liabil work equiti research
tabl eisai ratio multipl
pleas see import disclosur inform page report
eisai co ltd produc prescript drug medic equip sell mainli sale agent subsidiari
subsidiari compani produc sell diagnost drug eisai also market product relat compani us
europ asia compani also manufactur sell food livestock feed chemic agrochem
valuat target eisai equat ev/cor ebitda line eisai three-year histor
averag feel eisai may deserv trade premium peer compani high level corpor govern
risk biggest risk eisai share price revenu profit estim risk alzheim drug aducanumab
approv fda regulatori author also risk estim lenvima high
estim eisai book lenvima-link mileston per year next five year mileston payment smaller
absent altogeth given year would neg impact profit compar forecast regulatori chang
affect price big market us could also neg impact compani profit
pt base appli price-to-earnings multipl non-gaap ep support dcf risk includ ip litig
biosimilar price competit
stephen barker certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
naoya miura certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
registr non-u analyst stephen barker employ jefferi japan limit non-u affili jefferi llc
registered/qualifi research analyst finra analyst may associ person jefferi llc
finra member firm therefor may subject finra rule restrict commun subject
compani public appear trade secur held research analyst
registr non-u analyst naoya miura employ jefferi japan limit non-u affili jefferi llc
registered/qualifi research analyst finra analyst may associ person jefferi llc
finra member firm therefor may subject finra rule restrict commun subject
compani public appear trade secur held research analyst
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom
seek updat research appropri variou regul may prevent us asid certain industri
report publish period basi larg major report publish irregular interv appropri analyst
articl articl
